If the Market Crashes, This Is the 1 Space Stock I Can't Wait to Buy

Rocket Lab reported record Q2 revenue of $234 million, up 62% year over year, while backlog rose 137% to $2.36 billion and new launch contracts exceeded $437 million. Growth is increasingly supported by government business, including a $266 million U.S. Space Force launch contract and a $397 million Space Force spacecraft-build-and-launch award. The company held roughly $2.1 billion of cash plus $258 million in marketable securities, but remains unprofitable and faces material execution risk on its larger reusable Neutron rocket; its nearly $40 billion valuation, or about 50x trailing sales, leaves the shares vulnerable in a market selloff.

Analysis

RKLB is transitioning from a single-program launch multiple toward a defense-space prime/vertical-integration multiple, but the market is already capitalizing much of that outcome. The key underwriting question is not backlog growth; it is conversion quality: funded versus option backlog, milestone/payment timing, and whether higher-value spacecraft programs lift gross margin faster than the company’s fixed-cost base and Neutron development spend. Government awards can reduce demand volatility, but they also introduce program-concentration, procurement-delay, and working-capital risk that a headline backlog figure obscures.

Near term, a broad risk-off move would likely hit RKLB disproportionately because its valuation is sensitive to terminal-margin and Neutron-success assumptions rather than current earnings. Over the next 1-3 months, the relevant catalysts are Neutron schedule/milestone disclosures, award funding detail, quarterly cash burn, and any evidence that space-systems revenue is scaling without margin dilution. A miss on development spend or a slip in first-launch timing would compress the equity well before a technical failure, while successful engine and integration milestones could support another leg higher.

The non-obvious competitive effect is that a credible Neutron schedule pressures the economics of dedicated medium-lift launch and constellation deployment, but it does not automatically displace SpaceX; the more realistic early opportunity is national-security customers seeking assured-access diversification. That favors RKLB’s strategic relevance but may cap launch pricing and require heavy capex for years. The contrarian view is that investors may be assigning too much scarcity value to an eventual second U.S. reusable medium-lift platform before its cost-per-launch and cadence are demonstrated; defense contract wins alone should not justify a premium multiple if cash conversion remains negative.

Key Decisions for Investors

• Do not chase RKLB at current momentum; establish a watch level tied to a 30-40% risk-off drawdown or a valuation below roughly 25-30x forward sales, contingent on no Neutron schedule slip. The expected reward is renewed multiple expansion on de-risking; risk is that lower valuation reflects a genuine program delay.
• For a 1-3 month tactical position, use a defined-risk RKLB call spread only after the next earnings release confirms cash runway, gross-margin progression, and unchanged Neutron milestones. Avoid naked upside exposure ahead of development updates, where a schedule revision can produce gap risk.
• Pair a small long RKLB position against short ASTS or a broad high-beta space proxy only if RKLB demonstrates contract-funded backlog conversion and stable launch cadence; the intended exposure is to defense-space execution rather than speculative space beta. Exit if quarterly operating cash burn accelerates materially or Neutron timing moves out by more than one reporting period.
• Monitor defense appropriations, Space Force program funding, and contract option exercises over the next 6-18 months. A continuing-resolution environment, delayed appropriations, or options left unexercised would challenge the assumption that announced awards translate into near-term revenue and cash receipts.